Genomics is changing how we understand cancer

The next chapter is about turning insight into action.

Precision oncology is entering a new era.

As next-generation sequencing, liquid biopsy and advanced genomic technologies continue to evolve, the opportunity is no longer simply to generate more data — but to translate increasingly complex genomic information into clinically meaningful insights.

Insights that can help us:

• Understand disease more precisely
• Inform clinical decisions
• Guide treatment
• Monitor disease
• Ultimately, improve patient care

Join SOPHiA GENETICS for an evening of expert discussion exploring the next chapter in precision oncology — where genomic data, clinical expertise and innovation converge to bring precision medicine closer to the patient.

Meet the Experts

DR. KOJO S. ELENITOBA-JOHNSON, MD
Chair, Department of Pathology and Laboratory Medicine
Memorial Sloan Kettering Cancer Center

Dr. Kojo S. Elenitoba-Johnson is a physician-scientist specialising in hematopathology and molecular genetic pathology, with more than three decades of experience in pathology and molecular pathology.

His work focuses on genomic and proteomic alterations in lymphoma and their diagnostic and therapeutic applications, including the use of advanced genomic approaches such as next-generation sequencing in hematologic malignancies.

DR. OMShree
Scientific Officer, Molecular Diagnostics & Translational Medicine
Tata Memorial Centre

Dr. Omshree brings a clinical and translational perspective from Tata Memorial Centre, one of India's leading institutions in cancer care, research and education.

Her work contributes to the evolving role of molecular diagnostics and genomic medicine in cancer, and how advances in genomics can translate into meaningful clinical practice and patient care.

DR. SRIDHAR SIVASUBBU
Chief Diagnostics & Research Officer & Lab Director
Karkinos Healthcare

Dr. Sridhar Sivasubbu brings extensive expertise across genomics, molecular diagnostics and precision medicine, with a strong focus on translating genomic science into healthcare.

At Karkinos Healthcare, his work sits at the intersection of diagnostics, research and cancer genomics. He has also been involved in initiatives such as the Bharat Cancer Genome Atlas, supporting the development of genomic resources to advance cancer research and more personalised approaches to cancer care in India.

El próximo 15 de octubre, en las instalaciones de INMEGEN, se llevará a cabo el GENOMiCS INSIGHTS Day México, un encuentro que reunirá a líderes clínicos, investigadores y especialistas en genómica para compartir experiencias y discutir el papel creciente de la medicina de precisión en la atención de pacientes oncológicos.

Durante la jornada se abordarán temas clave como los avances en programas de prevención y vigilancia genómica, la evolución del perfilamiento molecular desde tejido hasta biopsia líquida, y la implementación de programas de secuenciación a gran escala en instituciones de referencia internacionales. Asimismo, se presentarán experiencias regionales sobre el uso de la biopsia líquida para apoyar la toma de decisiones terapéuticas en cáncer y casos reales de adopción de tecnologías genómicas en la práctica clínica.

El evento contará con ponentes de reconocidas instituciones de México, Estados Unidos y Brasil, quienes compartirán perspectivas clínicas, operativas y científicas sobre la integración de la genómica en los sistemas de salud. La jornada finalizará con una mesa redonda y un espacio de networking, promoviendo el intercambio de conocimientos y la colaboración entre los profesionales de la región.

What: SOPHiA GENETICS exclusive networking event

Date: 15 de octobre

Time: 8h:30-13h:30

Where: INMEGEN

Agenda

Why Attend?

Descubra SOPHiA DDM™: una plataforma compatible con múltiples tecnologías, con infinitas posibilidades

Conozca cómo SOPHiA DDM™ permite realizar análisis precisos en diversas áreas de la medicina, desde oncología hasta enfermedades raras.

Aborde los desafíos actuales de la práctica clínica y la investigación

Participe en una conversación sobre el futuro de las instituciones de salud e investigación y descubra cómo aprovechar el potencial de los datos de secuenciación de nueva generación (NGS) para generar resultados rápidos, sólidos y accionables que faciliten una toma de decisiones informada.

Conecte con líderes de opinión y expertos del sector

Interactúe con colegas, investigadores y usuarios de la plataforma SOPHiA DDM™ en un espacio diseñado para el intercambio de conocimientos, experiencias y oportunidades de colaboración científica.

📍 National Institutes of Health (NIH), Kuala Lumpur, Malaysia | ⏱️ 2-hour session (10am - 12pm) | 8 October 2026

An exclusive educational session for government laboratory specialists, bioinformaticians, and pathologists

About This Session

As genomic testing volumes continue to rise across public healthcare systems, laboratories are under increasing pressure to deliver faster, more consistent, and more clinically actionable results.

SOPHiA GENETICS, in partnership with Science Vision, invites government stakeholders at the forefront of genomic diagnostics in Malaysia to a dedicated educational session, offering a substantive discussion of the analytical and interpretive challenges facing genomic laboratories today, and how AI-powered platforms such as SOPHiA DDM™ are helping address them.

Participants will gain practical insight into modern genomic workflows, observe the platform in a live demonstration, and have the opportunity to contribute their own laboratory's challenges to the discussion.

Why Attend

• Understand the real bottlenecks — variant analysis volume, inconsistent pipelines, and manual curation burden — and how they can be addressed
• See it live — a guided walkthrough of the SOPHiA DDM™ platform, from raw variant data to a clinical-ready report
• Learn from peers — hear directly from a regional institution about their journey adopting data-driven genomic analysis
• Shape the discussion — an open forum to surface your lab's specific challenges, not a one-way presentation
• Leave with a clear next step — whether that's a technical visit, a pilot evaluation, or a dedicated technical consultation

Agenda

Who Should Attend

Government laboratory specialists, bioinformaticians, pathologists, and public healthcare stakeholders involved in genomic testing and analysis.

From genomic innovation to real-world implementation: exploring the future of liquid biopsy and precision oncology across the Middle East.

The conversation around precision medicine is rapidly evolving. In this on-demand session, leading oncology experts, healthcare decision-makers, pharmaceutical partners, policy representatives, and key opinion leaders come together to explore how liquid biopsy is transforming cancer care delivery and genomic testing strategies across the region.

Watch the full recording to hear expert perspectives, real-world experiences, and practical insights from leading institutions.

What You'll Discover

This high-level discussion explores the evolving role of liquid biopsy in precision oncology and the opportunities to bring advanced genomic testing closer to patients.

Decentralizing precision oncology
Learn how Memorial Sloan Kettering Cancer Center (MSK) and SOPHiA GENETICS collaborated to decentralize MSK’s renowned genomic assay, MSK-ACCESS™, powered with SOPHiA DDM™ for liquid biopsy applications.

From innovation to implementation
Hear real-world perspectives on implementing advanced genomic testing and scaling precision oncology solutions in clinical practice.

Regional insights from the Middle East
Discover how healthcare leaders in the region are approaching innovation, scalability, and the integration of genomic testing into cancer care.

The evolving role of liquid biopsy
Explore how liquid biopsy can contribute to more accessible and actionable genomic testing strategies and support the continued evolution of precision medicine.

Watch the Expert Discussion

Featuring perspectives from leading oncology, genomics, and precision medicine experts from Memorial Sloan Kettering Cancer Center, M42, and SOPHiA GENETICS.

Clonal hematopoiesis of indeterminate potential (CHIP) is an increasingly recognized challenge in liquid biopsy analysis. Somatic variants arising in hematopoietic progenitor cells can appear in cell-free DNA (cfDNA) analyses, mimicking tumor-derived signals and complicating result interpretation. Correctly assigning these variants is critical – both to avoid false tumor calls and to capture CHIP's emerging role as an independent biomarker for cancer risk and outcomes.

MSK-ACCESS® powered with SOPHiA DDM™ incorporates matched white blood cell (WBC) DNA sequencing to systematically distinguish CHIP and germline variants from true tumor-derived signals. In this poster presentation, Florian Klemm shares findings from a multicenter, retrospective study evaluating CHIP detection across different cfDNA analysis approaches in individuals with colorectal, prostate, pancreatic, and breast cancer. This research was conducted in collaboration with Synnovis, UK.

Watch to discover:

• How MSK-ACCESS® powered with SOPHiA DDM™ achieved 97.9% positive percent agreement with orthogonal results.
• How CHIP assignment differs between cfDNA-only and matched WBC sequencing approaches, despite overall analytical concordance
• Why matched WBC sequencing is essential for reliable differentiation of CHIP, germline, and somatic variants in precision oncology

Presenter

Florian Klemm, Technical Product Manager Expert Lead, SOPHiA GENETICS, Rolle, Switzerland

Dr. Florian Klemm is a physician-scientist and tumor immunologist with deep expertise in next‑generation sequencing (NGS), liquid biopsy technologies, and translational oncology. As a Technical Product Manager Expert Lead at SOPHiA GENETICS, he drives the product design of decentralized cfDNA NGS solutions. Most notably, he has led the development of MSK‑ACCESS® powered with SOPHiA DDM™ where he led cross‑functional teams spanning assay development, bioinformatics, tertiary annotation, and software.

With more than a decade of research experience across the Ludwig Institute for Cancer Research at the University of Lausanne, Switzerland, Memorial Sloan Kettering Cancer Center, New York, USA and the University of Göttingen, Germany, Florian has an extensive track record applying NGS, multidimensional genomics, spatial tissue analysis, and large‑scale datasets to advance understanding of tumor biology and tumor–immune interactions. His first‑author publication in Cell (2020) highlights his contributions to mapping immune cell states in brain malignancies. He is passionate about bridging clinical insight, high‑throughput technologies, and data‑driven approaches to deliver impactful solutions that improve patient outcomes.

The SOPHiA GENETICS™ Global Precision Medicine Forum returns to ESMO! Join us on October 22^nd at 3:00 PM CET at the Novotel Madrid Campo de las Naciones, Madrid, Spain, for its 2026 edition.

The liquid biopsy movement continues. Building on the conversation started by SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center (MSK) at ASCO 2026, this forum explores how expanding access to liquid biopsy is now translating into clinical action. Join the pioneers driving this transformation as they share real-world insights from routine practice, demonstrate how decentralized testing is shaping patient care, and reveal how the same model is enabling the next generation of precision oncology biomarkers.

Join Pharma and Biotech leaders, oncology KOLs, and diagnostic partners to explore The Liquid Biopsy Movement: From Access to Action, and how it is reshaping the future of cancer care.

Across different sessions, the forum will explore:

• Liquid biopsy: From Deployment to Daily Practice
• A Blueprint for the Next Generation Biomarkers
• Strategic Innovation Through Partnerships
• Validation as a Shared Responsibility

Don’t miss this unique opportunity and reserve your spot now!

What began at our inaugural forum in 2024 has since taken shape across the field. SOPHiA GENETICS and the Memorial Sloan Kettering Cancer Center (MSK) return to ASCO to convene leading voices in precision oncology, this time with a singular focus: the liquid biopsy revolution. 

This forum traces the journey from a pioneering academic-industry collaboration with MSK to a global movement reshaping how cancer is detected, monitored, and treated. 

Topics:

• From One Lab to the World: Liquid Biopsy as a Leapfrog Technology
• The Power of the Network in Expanding Access to Advanced NGS LBx
• Strategic Partnerships: The Engine Drivers
• Leading Advances In Precision Oncology With Open Innovation

Speakers:

• Bob T. Li, MD, PhD, MPH – Senior Vice President, Global Head of Medical Affairs, Oncology, AstraZeneca
• Pedram Razavi, MD, PhD – Director, Liquid Biopsy and Cancer Genomics & MSK Biomarker Development Program, Memorial Sloan Kettering Cancer Center
• Kojo Elenitoba-Johnson, MD – Chair of the Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center
• Dale Muzzey – Chief Scientific Officer, Myriad Genetics
• John Longshore, PhD, FACMG – Head of Scientific Affairs Global Oncology Diagnostics, AstraZeneca
• Nicola Normanno, MD – Scientific Director, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”
• Lou Welebob – Senior Vice President of BioPharma Companion Diagnostics, Myriad Genetics
• Ross Muken – President, SOPHiA GENETICS
• Philippe Menu, MD, PhD – EVP, Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS
• Jess Lambe - Vice President & Managing Director, BioPharma Business Development, SOPHiA

Join SOPHiA GENETICS™ and ARC Regulatory for an exclusive Industry Reception bringing together precision medicine and pharma leaders in Boston on July 21^st.

Following our recently announced Master Collaboration Agreement, this event will spotlight our integrated solution for pharma companies across the clinical development lifecycle in Europe, combining ARC's IVDR regulatory expertise with SOPHiA GENETICS' NGS technology and CE-IVD track record.

You’ll hear directly from both teams about key milestones, including the co-development of a Clinical Trial Assay (CTA) designed to accelerate patient recruitment in European clinical trials.

Accelerate with Impact: Expanding Patient Access to Precision Medicine Across the EU

The programme will be followed by a networking reception, offering a unique opportunity to connect with peers and leaders shaping the future of precision medicine.

Reserve your spot today!

El GENOMiCS INSIGHTS Day Panama se llevará a cabo el próximo 30 de julio, en el restaurante Maito. Este encuentro reunirá a expertos, líderes clínicos y profesionales del área de la genómica para explorar los avances más recientes en medicina de precisión y el impacto creciente de las tecnologías genómicas en la práctica clínica.   Durante la jornada abordaremos temas clave como la transformación del diagnóstico genómico en Latinoamérica, las nuevas posibilidades clínicas de la biopsia líquida y experiencias reales de implementación en la práctica clínica con la plataforma SOPHiA DDM™.   Este espacio también busca fomentar el intercambio de experiencias y la conversación entre profesionales del sector, promoviendo el avance de la medicina genómica en la región.   A continuación, encontrará la agenda preliminar del evento.

What: SOPHiA GENETICS Exclusive Networking event

Where: Restaurante Maito

Date: 30 de julio

Time: 18h00-21h:00

Agenda

Why Attend?

Discover SOPHiA DDM™ – One platform, universally compatible, endless possibilities

Discover how SOPHiA DDM™ enables accurate analysis across multiple disease areas – from oncology to inherited disorders

Connect with your peers

Enjoy a networking environment with your peers and users of SOPHiA DDM™ Platform.

Discuss

Discuss the future of research and healthcare institutions to harness NGS data for quick, robust, and actionable insights, guiding best decisions.

We are thrilled to be back at the 16^th World Clinical Biomarkers & Companion Diagnostics Summit. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.

Our team will be happy to see you join our Plenary Talk and our Co-hosted Engager with Myriad Genetics.

Plenary Talk on Tuesday, October 6^th, from 5.40 to 6.10 pm.

“The Power of Modular CGP: Enabling Precision Oncology Across Drug Development”

Mike Berger, PhD, Co-Director, Marie Josee & Henry Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center

Julien Pontis, PhD, Head of CDx & Clinical Diagnostics, SOPHiA GENETICS

Join this session to explore how MSK-IMPACT® Flex powered with SOPHiA DDM™ is reshaping the future of precision medicine. In this session you will:

• Explore the origins of MSK-IMPACT™ and its real-world impact on patient care.
• Gain insights into the assay’s robust analytical performance at scale, enabling decentralized sites across the world to generate concordant and high-quality data.
• Discover the agile and modular design of MSK-IMPACT® Flex powered with SOPHiA DDM™, which enhances testing efficiency through tailored biomarker coverage, while providing the flexibility to add biomarkers as needed.

Understand how a flexible, future-proof CGP infrastructure helps pharma keep pace with an evolving biomarker landscape, and how SOPHiA GENETICS is already delivering this across the drug development continuum through hands-on partnerships with key diagnostic players.

Co-hosted Engager, coupled with a networking dinner, on Tuesday, October 6^th from 7.30 to 10.00 pm.

“Pioneering Precision Medicine: A New Model for CDx Development & Commercialization”

In this workshop, we will explore how a groundbreaking industry collaboration is rethinking current CDx approaches through a hybrid model designed for rapid scalability and access in precision medicine.

This is an invitation-only engager session. If you are interested in attending, please contact the Hanson Wade team.